請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78843
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 賈景山,李正? | |
dc.contributor.author | Ling-Ying Wei | en |
dc.contributor.author | 魏鈴穎 | zh_TW |
dc.date.accessioned | 2021-07-11T15:23:28Z | - |
dc.date.available | 2022-03-11 | |
dc.date.copyright | 2019-03-11 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-01-29 | |
dc.identifier.citation | [1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
[2] Sturgis EM, Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007;110:1429-35. [3] Hsu WL, Chien YC, Chiang CJ, Yang HI, Lou PJ, Wang CP, et al. Lifetime risk of distinct upper aerodigestive tract cancers and consumption of alcohol, betel and cigarette. Int J Cancer. 2014;135:1480-6. [4] Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol. 2009;45:309-16. [5] Thomson PJ, Hamadah O. Cancerisation within the oral cavity: the use of 'field mapping biopsies' in clinical management. Oral Oncol. 2007;43:20-6. [6] Genden EM, Ferlito A, Bradley PJ, Rinaldo A, Scully C. Neck disease and distant metastases. Oral Oncol. 2003;39:207-12. [7] Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Munoz-Guerra M, Cruces J, et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer. 2005;113:899-910. [8] Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759-71. [9] Eiro N, Vizoso FJ. Inflammation and cancer. World J Gastrointest Surg. 2012;4:62-72. [10] Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860-7. [11] Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073-81. [12] Multhoff G, Molls M, Radons J. Chronic inflammation in cancer development. Front Immunol. 2011;2:98. [13] Virchow R. An Address on the Value of Pathological Experiments. Br Med J. 1881;2:198-203. [14] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74. [15] Lee CH, Lee JM, Wu DC, Hsu HK, Kao EL, Huang HL, et al. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer. 2005;113:475-82. [16] Perez-Sayans M, Somoza-Martin JM, Barros-Angueira F, Reboiras-Lopez MD, Gandara Rey JM, Garcia-Garcia A. Genetic and molecular alterations associated with oral squamous cell cancer (Review). Onco Rep. 2009;22:1277-82. [17] Meurman JH. Oral microbiota and cancer. J Oral Microbiol. 2010;2. [18] Rao SK, Pavicevic Z, Du Z, Kim JG, Fan M, Jiao Y, et al. Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. J Biol Chem. 2010;285:32512-21. [19] Chang LY, Wan HC, Lai YL, Kuo YF, Liu TY, Chen YT, et al. Areca nut extracts increased expression of inflammatory cytokines, tumor necrosis factor-alpha, interleukin-1beta, interleukin-6 and interleukin-8, in peripheral blood mononuclear cells. J Perio Res. 2009;44:175-83. [20] Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010;34:J258-65. [21] Ji WT, Chuang YC, Chen HP, Lee CC, Chen JY, Yang SR, et al. Areca nut extracts exert different effects in oral cancer cells depending on serum concentration: A clue to the various oral alterations in betel quid chewers. Toxicology Reports. 2014;1:1087-95. [22] Lee JJ, Kao KC, Chiu YL, Jung CJ, Liu CJ, Cheng SJ, et al. Enrichment of Human CCR6(+) Regulatory T Cells with Superior Suppressive Activity in Oral Cancer. J Immunol. 2017;199:467-76. [23] Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, et al. ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer. 2010;46:1712-23. [24] Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today. 2000;6:324-9. [25] Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999;59:5002-11. [26] Aboseif S, El-Sakka A, Young P, Cunha G. Mesenchymal reprogramming of adult human epithelial differentiation. Differentiation. 1999;65:113-8. [27] Drews J. Paul Ehrlich: magister mundi. Nat Rev Drug Discov. 2004;3:797-801. [28] Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science. 2013;339:286-91. [29] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883-99. [30] Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev. 2008;18:11-8. [31] McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science. 2000;289:1202-6. [32] Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner. Cancer Cell. 2010;17:135-47. [33] Hassona Y, Cirillo N, Lim KP, Herman A, Mellone M, Thomas GJ, et al. Progression of genotype-specific oral cancer leads to senescence of cancer-associated fibroblasts and is mediated by oxidative stress and TGF-beta. Carcinogenesis. 2013;34:1286-95. [34] Kellermann MG, Sobral LM, da Silva SD, Zecchin KG, Graner E, Lopes MA, et al. Mutual paracrine effects of oral squamous cell carcinoma cells and normal oral fibroblasts: induction of fibroblast to myofibroblast transdifferentiation and modulation of tumor cell proliferation. Oral Oncol. 2008;44:509-17. [35] Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. 2001;411:375-9. [36] Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012;21:309-22. [37] Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012;196:395-406. [38] Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253-68. [39] Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 2012;72:2473-80. [40] Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol Cancer Res. 2011;9:1658-67. [41] Muraoka K, Shimizu K, Sun X, Zhang YK, Tani T, Hashimoto T, et al. Hypoxia, but not reoxygenation, induces interleukin 6 gene expression through NF-kappa B activation. Transplantation. 1997;63:466-70. [42] Linnskog R, Jonsson G, Axelsson L, Prasad CP, Andersson T. Interleukin-6 drives melanoma cell motility through p38alpha-MAPK-dependent up-regulation of WNT5A expression. Mol Oncol. 2014;8:1365-78. [43] Kim MS, Lee WS, Jeong J, Kim SJ, Jin W. Induction of metastatic potential by TrkB via activation of IL6/JAK2/STAT3 and PI3K/AKT signaling in breast cancer. Oncotarget. 2015;6:40158-71. [44] Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer. 2005;41:2502-12. [45] Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006;66:3162-8. [46] Klampfer L. Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs. Curr Cancer Drug Tar. 2006;6:107-21. [47] Yin W, Cheepala S, Roberts JN, Syson-Chan K, DiGiovanni J, Clifford JL. Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol Cancer. 2006;5:15. [48] Shinriki S, Jono H, Ota K, Ueda M, Kudo M, Ota T, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res. 2009;15:5426-34. [49] Wang YF, Chang SY, Tai SK, Li WY, Wang LS. Clinical significance of interleukin-6 and interleukin-6 receptor expressions in oral squamous cell carcinoma. Head & Neck. 2002;24:850-8. [50] Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113:750-7. [51] Choudhary MM, France TJ, Teknos TN, Kumar P. Interleukin-6 role in head and neck squamous cell carcinoma progression. J Oto Laryngol-Head Neck. 2016;2:90-7. [52] De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer. 2005;5:42. [53] Allen C, Duffy S, Teknos T, Islam M, Chen Z, Albert PS, et al. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res. 2007;13:3182-90. [54] Neta R, Perlstein R, Vogel SN, Ledney GD, Abrams J. Role of interleukin 6 (IL-6) in protection from lethal irradiation and in endocrine responses to IL-1 and tumor necrosis factor. J Exp Med. 1992;175:689-94. [55] Wu CT, Chen MF, Chen WC, Hsieh CC. The role of IL-6 in the radiation response of prostate cancer. Radiat Oncol. 2013;8:159. [56] Sen M, Paul K, Freilino ML, Li H, Li C, Johnson DE, et al. Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects. Mol Med. 2014;20:46-56. [57] Eulenfeld R, Dittrich A, Khouri C, Muller PJ, Mutze B, Wolf A, et al. Interleukin-6 signalling: more than Jaks and STATs. Eur J Cell Biol. 2012;91:486-95. [58] Ernst M, Jenkins BJ. Acquiring signalling specificity from the cytokine receptor gp130. Trends in genetics : TIG. 2004;20:23-32. [59] Chow MT, Luster AD. Chemokines in cancer. Cancer Immunol Res. 2014;2:1125-31. [60] Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559-72. [61] Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004;4:540-50. [62] Hazan RB, Kang L, Whooley BP, Borgen PI. N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhes Commun. 1997;4:399-411. [63] Orimo A, Tomioka Y, Shimizu Y, Sato M, Oigawa S, Kamata K, et al. Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin Cancer Res. 2001;7:3097-105. [64] Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295-307. [65] Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263-74. [66] Wolff HA, Rolke D, Rave-Frank M, Schirmer M, Eicheler W, Doerfler A, et al. Analysis of chemokine and chemokine receptor expression in squamous cell carcinoma of the head and neck (SCCHN) cell lines. Radiat Environ Biophys. 2011;50:145-54. [67] Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest. 2010;120:2423-31. [68] Wang D, Wang H, Brown J, Daikoku T, Ning W, Shi Q, et al. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med. 2006;203:941-51. [69] Li L, Xu L, Yan J, Zhen ZJ, Ji Y, Liu CQ, et al. CXCR2-CXCL1 axis is correlated with neutrophil infiltration and predicts a poor prognosis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2015;34:129. [70] Benelli R, Stigliani S, Minghelli S, Carlone S, Ferrari N. Impact of CXCL1 overexpression on growth and invasion of prostate cancer cell. Prostate. 2013;73:941-51. [71] Ogata H, Sekikawa A, Yamagishi H, Ichikawa K, Tomita S, Imura J, et al. GROalpha promotes invasion of colorectal cancer cells. Oncol Rep. 2010;24:1479-86. [72] Yang G, Rosen DG, Zhang Z, Bast RC, Jr., Mills GB, Colacino JA, et al. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. PNAS. 2006;103:16472-7. [73] Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A, et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis. 2009;30:698-705. [74] Tjomsland V, Spangeus A, Valila J, Sandstrom P, Borch K, Druid H, et al. Interleukin 1alpha sustains the expression of inflammatory factors in human pancreatic cancer microenvironment by targeting cancer-associated fibroblasts. Neoplasia. 2011;13:664-75. [75] Jung DW, Che ZM, Kim J, Kim K, Kim KY, Williams D, et al. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: a pivotal role of CCL7. Int J Cancer. 2010;127:332-44. [76] Jan JC, Hsu WH, Liu SA, Wong YK, Poon CK, Jiang RS, et al. Prognostic factors in patients with buccal squamous cell carcinoma: 10-year experience. J Oral Maxillofac Surg. 2011;69:396-404. [77] Clark AG, Vignjevic DM. Modes of cancer cell invasion and the role of the microenvironment. Curr Opin Cell Biol. 2015;36:13-22. [78] Bankfalvi A, Piffko J. Prognostic and predictive factors in oral cancer: the role of the invasive tumour front. J Oral Pathol Med. 2000;29:291-8. [79] Kurokawa H, Zhang M, Matsumoto S, Yamashita Y, Tanaka T, Tomoyose T, et al. The relationship of the histologic grade at the deep invasive front and the expression of Ki-67 antigen and p53 protein in oral squamous cell carcinoma. J Oral Pathol Med. 2005;34:602-7. [80] Piffko J, Bankfalvi A, Ofner D, Rasch D, Joos U, Schmid KW. Standardized demonstration of silver-stained nucleolar organizer regions-associated proteins in archival oral squamous cell carcinomas and adjacent non-neoplastic mucosa. Mod Pathol. 1997;10:98-104. [81] Shinohara M, Hiraki A, Ikebe T, Nakamura S, Kurahara S, Shirasuna K, et al. Immunohistochemical study of desmosomes in oral squamous cell carcinoma: correlation with cytokeratin and E-cadherin staining, and with tumour behaviour. J Pathol. 1998;184:369-81. [82] Wang X, Zhang J, Fan M, Zhou Q, Deng H, Aisharif MJ, et al. The expression of E-cadherin at the invasive tumor front of oral squamous cell carcinoma: immunohistochemical and RT-PCR analysis with clinicopathological correlation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:547-54. [83] Ikebe T, Shinohara M, Takeuchi H, Beppu M, Kurahara S, Nakamura S, et al. Gelatinolytic activity of matrix metalloproteinase in tumor tissues correlates with the invasiveness of oral cancer. Clin Exp Metastasis. 1999;17:315-23. [84] Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck. 1999;21:627-38. [85] Berndt A, Borsi L, Hyckel P, Kosmehl H. Fibrillary co-deposition of laminin-5 and large unspliced tenascin-C in the invasive front of oral squamous cell carcinoma in vivo and in vitro. J Cancer Res Clin Oncol. 2001;127:286-92. [86] Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125:5591-6. [87] Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239-52. [88] Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147:992-1009. [89] Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516. [90] Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol. 2013;230:241-8. [91] Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007;211:19-26. [92] Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets. 2003;7:385-97. [93] Sternlicht MD, Bergers G. Matrix metalloproteinases as emerging targets in anticancer therapy: status and prospects. Emerging Therapeutic Targets. 2000;4:609-33. [94] McKerrow JH, Bhargava V, Hansell E, Huling S, Kuwahara T, Matley M, et al. A functional proteomics screen of proteases in colorectal carcinoma. Mol Med. 2000;6:450-60. [95] Zhang W, Matrisian LM, Holmbeck K, Vick CC, Rosenthal EL. Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo. BMC Cancer. 2006;6:52. [96] Fan HX, Chen Y, Ni BX, Wang S, Sun M, Chen D, et al. Expression of MMP-1/PAR-1 and patterns of invasion in oral squamous cell carcinoma as potential prognostic markers. Onco Targets Ther. 2015;8:1619-26. [97] Fernandes JV, Cobucci RN, Jatoba CA, Fernandes TA, de Azevedo JW, de Araujo JM. The role of the mediators of inflammation in cancer development. Pathol Oncol Res. 2015;21:527-34. [98] Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335-48. [99] Criscitiello C, Esposito A, Curigliano G. Tumor-stroma crosstalk: targeting stroma in breast cancer. Curr Opin Oncol. 2014;26:551-5. [100] Drigotas M, Affolter A, Mann WJ, Brieger J. Reactive oxygen species activation of MAPK pathway results in VEGF upregulation as an undesired irradiation response. J Oral Pathol Med. 2013;42:612-9. [101] Lee JJ, Chang YL, Lai WL, Ko JY, Kuo MY, Chiang CP, et al. Increased prevalence of interleukin-17-producing CD4(+) tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck. 2011;33:1301-8. [102] Dudas J, Fullar A, Bitsche M, Schartinger V, Kovalszky I, Sprinzl GM, et al. Tumor-produced, active interleukin-1beta regulates gene expression in carcinoma-associated fibroblasts. Exp Cell Res. 2011;317:2222-9. [103] Elias JA, Freundlich B, Kern JA, Rosenbloom J. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest. 1990;97:1439-45. [104] Lee CH, Syu SH, Liu KJ, Chu PY, Yang WC, Lin P, et al. Interleukin-1 beta transactivates epidermal growth factor receptor via the CXCL1-CXCR2 axis in oral cancer. Oncotarget. 2015;6:38866-80. [105] Fullar A, Kovalszky I, Bitsche M, Romani A, Schartinger VH, Sprinzl GM, et al. Tumor cell and carcinoma-associated fibroblast interaction regulates matrix metalloproteinases and their inhibitors in oral squamous cell carcinoma. Exp Cell Res. 2012;318:1517-27. [106] Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007;110:1911-28. [107] Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Brit J Cancer. 2003;88:1721-6. [108] Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9:4653-65. [109] Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer cell. 2008;13:7-9. [110] Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J Clin Invest. 1998;102:1385-92. [111] Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. PNAS. 2000;97:4227-32. [112] Rubin Grandis J, Zeng Q, Drenning SD. Epidermal growth factor receptor--mediated stat3 signaling blocks apoptosis in head and neck cancer. The Laryngoscope. 2000;110:868-74. [113] Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer Res. 2003;63:2948-56. [114] Deorukhkar A, Krishnan S. Targeting inflammatory pathways for tumor radiosensitization. Biochem Pharmacol. 2010;80:1904-14. [115] Bochet L, Meulle A, Imbert S, Salles B, Valet P, Muller C. Cancer-associated adipocytes promotes breast tumor radioresistance. Biochem Biophys Res Commun. 2011;411:102-6. [116] Chen Y, Zhang F, Tsai Y, Yang X, Yang L, Duan S, et al. IL-6 signaling promotes DNA repair and prevents apoptosis in CD133+ stem-like cells of lung cancer after radiation. Radiat Oncol. 2015;10:227. [117] Matsuoka Y, Nakayama H, Yoshida R, Hirosue A, Nagata M, Tanaka T, et al. IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma. Brit J Cancer. 2016;115:1234-44. [118] Liu Y, Tian HY, Yan XL, Fan FL, Wang WP, Han JL, et al. Serotonin inhibits apoptosis of pulmonary artery smooth muscle cell by pERK1/2 and PDK through 5-HT1B receptors and 5-HT transporters. Cardiovasc Pathol. 2013;22:451-7. [119] Han S, Li Z, Master LM, Master ZW, Wu A. Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway. Brit J Cancer. 2014;111:1400-9. [120] Herrera M, Herrera A, Dominguez G, Silva J, Garcia V, Garcia JM, et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci. 2013;104:437-44. [121] Jewett A, Head C, Cacalano NA. Emerging mechanisms of immunosuppression in oral cancers. J Dent Res. 2006;85:1061-73. [122] Panda S, Padhiary SK, Routray S. Chemokines accentuating protumoral activities in oral cancer microenvironment possess an imperious stratagem for therapeutic resolutions. Oral Oncol. 2016;60:8-17. [123] Osuala KO, Sameni M, Shah S, Aggarwal N, Simonait ML, Franco OE, et al. Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migration. BMC Cancer. 2015;15:584. [124] Miyake M, Hori S, Morizawa Y, Tatsumi Y, Nakai Y, Anai S, et al. CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer. Neoplasia. 2016;18:636-46. [125] Wang D, Sun H, Wei J, Cen B, DuBois RN. CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. Cancer Res. 2017;77:3655-65. [126] Yuan M, Zhu H, Xu J, Zheng Y, Cao X, Liu Q. Tumor-Derived CXCL1 Promotes Lung Cancer Growth via Recruitment of Tumor-Associated Neutrophils. J Immunol Res. 2016;2016:6530410. [127] Chen X, Jin R, Chen R, Huang Z. Complementary action of CXCL1 and CXCL8 in pathogenesis of gastric carcinoma. Int J Clin Exp Pathol. 2018;11:1036-45. [128] Kim EK, Moon S, Kim DK, Zhang X, Kim J. CXCL1 induces senescence of cancer-associated fibroblasts via autocrine loops in oral squamous cell carcinoma. PLoS One. 2018;13:e0188847. [129] Zhang H, Yue J, Jiang Z, Zhou R, Xie R, Xu Y, et al. CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma. Cell Death Dis. 2017;8:e2790. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78843 | - |
dc.description.abstract | 口腔鱗狀上皮細胞癌的腫瘤微環境是由細胞激素、趨化激素及免疫反應等交 織而成的發炎環境,發炎不僅調控癌症進程,亦影響了臨床的治療效果。本文第一 部分將探討腫瘤介質(tumoral mediators)在腫瘤細胞的生長與放射線抗性之調節 機制,第二部分則探討腫瘤相關纖維母細胞(cancer associated fibroblasts)在腫瘤 微環境中受到發炎訊號刺激後的反應,及其反向對腫瘤細胞侵犯及遷移能力的影響。
在第一部分,免疫組織化學染色及癌症基因體圖譜計畫(The Cancer Genome Atlas)資料庫分析發現當組織高量表現 interleukin-6(IL-6)時,口腔癌患者有較 差的放射治療反應及預後。細胞實驗及動物實驗顯示 IL-6 可以促進腫瘤細胞的生 長,且 IL-6 可以抑制放射線引起之細胞凋亡,其機制是透過 ERK1/2 訊息傳導路 徑減少雙股 DNA 斷裂。在動物模型中,當腫瘤的 STAT3 被抑制且同時給予 IL-6 刺激時,其對放射線的治療效果最差,顯示在放射線抗性的調節機制中,ERK1/2 訊息路徑之角色較 STAT3 來得重要。在第二部分,我們發現 CXCL1 高量表現在 腫瘤相關纖維母細胞中,且其在腫瘤中的表現高時病患之存活率較差。此外,我們 發現 IL-1β 的表現與 CXCL1 有正相關,當腫瘤相關纖維母細胞受到 IL-1β 刺激或 與腫瘤細胞株共同培養時,CXCL1 會透過 NF-κB 訊息路徑大量表現。相對地當腫 瘤細胞受到 CXCL1 刺激或以腫瘤相關纖維母細胞之培養液刺激時,會增加腫瘤細 胞侵犯及遷徙的能力,其機制是透過增加 MMP1 之表現,表示在腫瘤相關纖維母 細胞與腫瘤細胞之間存在一個相互影響之關係。 根據研究發現,我們了解細胞激素與趨化激素如 IL-6 與 CXCL1 在口腔癌腫 瘤微環境中扮演了一個重要的角色。IL-6 可以透過 STAT3 相關及不相關的路徑來 調控腫瘤的生長與放射線抗性,並且是一個獨立於癌症分期、可以作為預測預後的 重要因子。未來可以期待,針對阻斷 IL-6/ERK 路徑的藥物為口腔癌疾病的控制與克服放射線抗性帶來輔助的效果。此外,腫瘤微環境中的 IL-1β 可以教育或活化腫瘤相關纖維母細胞,其產生之 CXCL1 可以進一步使腫瘤細胞侵犯及遷徙的能力增 加,兩者間相互關係調控了腫瘤的進程與惡化。總地來說,腫瘤細胞與基質細胞之 間透過發炎介質產生交互作用,在腫瘤生物學中影響甚鉅。 | zh_TW |
dc.description.abstract | Oral squamous cell carcinoma (OSCC) induces an inflammatory microenvironment comprised of cytokines, chemokines, and immune responses that may not only modulate cancer progression but also affect the therapeutic effects. The molecular mechanisms that how tumoral mediators regulate tumor growth and radioresistance and how cancer associated fibroblasts (CAFs) respond to inflammatory signals to influence cancer cell migration and invasion were investigated.
In the tumoral mediators part, immunostaining and TCGA data-based analysis indicated that high interleukin-6 (IL-6) expression in Situ were associated with a clinically unfavorable prognosis and radioresistance of patients with OSCC. Genetically and pharmalogically increased IL-6 induced cell proliferation in vitro and accelerated tumor growth in in vivo models. Experiments of radiation response demonstrated that IL-6 inhibited radiation-induced cell death by reducing DNA damage through ERK1/2- dependent signaling. In xenograft model, the worst tumor growth inhibition of irradiation was found in the IL-6 supplemented STAT3-knockdown group. In other words, blockade of ERK1/2 but not STAT3 pathway led to a substantial increase in apoptosis of OSCC cells. In the stromal interaction part, analysis of the TCGA dataset revealed that CXCL1 is associated with poor survival, and highly expressed in CAFs. In addition to CXCL1, IL-1β and CXCR2 are also highly expressed in OSCC and IL-1β mRNA levels positively correlate with CXCL1 expression. Furthermore, CAFs co-cultured with a poorly differentiated OSCC cell line SAS, or stimulated with IL-1β exhibit increased CXCL1 secretion in an NF-κB-dependent manner. Treatment of SAS cells with CAF-conditioned medium or CXCL1 increased their invasion and migration capabilities, indicating a reciprocal activation between CAFs and cancer cells. Moreover, CXCL-1 upregulated matrix metalloprotease-1 (MMP-1) expression and activity in CAFs. These findings demonstrate that the cytokines and chemokines, like IL-6 and CXCL1, play an important role in OSCC microenvironment. IL-6 promotes oral cancer cell growth and radioresistance in both STAT3-dependent and -independent manners and is a stage-independent predictor of poor prognosis. The possibility of targeting IL-6/ERK axis for a therapeutic strategy to suppress OSCC progression and overcome radioresistance could also be expected. Also, the induction of IL-1β following CXCL1 stimulation of CAFs mediates cancer cell migration and invasion, and there is a reciprocal dependency between CAFs and cancer cells. Taken together, crosstalk between cancer and stromal cells through the inflammatory mediators is known to be significantly involved in various aspects of tumor biology. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T15:23:28Z (GMT). No. of bitstreams: 1 ntu-108-F98422011-1.pdf: 31817757 bytes, checksum: 67a90c6438168ea805fe98e80c0d1eea (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 i
Acknowlegement ii 中文摘要 iii ABSTRACT v CONTENTS vii LIST OF FIGURES xii LIST OF TABLES xiv Chapter 1 Introduction 1 1.1 Epidemiology of oral cancer 1 1.2 Inflammation and cancer 2 1.3 Crosstalk mediators in tumor microenvironment 3 1.3.1 Immune system constitutes the basis of tumor microenvironment 3 1.3.2 Immune and cancer cells talk to each other via cytokines 5 1.3.3 Chemokines regulate tumor immunity and cancer cell behaviors directly and indirectly 7 1.3.4 Matrix Metalloproteinases degrade structural proteins of the extracellular matrix and cleave cell surface molecules 8 1.4 Unresolved questions and unmet needs 11 Chapter 2 Hypothesis and specific aims 13 2.1 Hypothesis 13 2.2 Specific aims 13 Chapter 3 Materials and Methods 15 3.1 Clinical specimen and TCGA analysis 15 3.1.1 OSCC specimen for immunohistochemistry study 15 3.1.2 OSCC specimen for CAF isolation 16 3.1.3 The Caner Genome Atlas (TCGA) analysis 16 3.2 Immunohistochemistry study 17 3.2.1 Staining protocols 17 3.2.2 Semi-quantitative analysis 17 3.3 Cell lines and cell culture 18 3.3.1 Human oral cancer cell line 18 3.3.2 Fibroblast culture 19 3.3.3 Cell transfection 19 3.3.4 Cell stimulation and cell treatments 20 3.3.5 Transwell co-cultures of CAF and OSCC cells 20 3.4 Isolation of RNA, reverse transcription PCR and Real-time PCR analysis 21 3.4.1 RNA extraction 21 3.4.2 Reverse Transcription PCR (RT-PCR) Analysis 22 3.4.3 Quantitative real-time PCR (qPCR) 22 3.5 Enzyme Linked Immunosorbent Assay (ELISA) 23 3.6 Migration and invasion assays 23 3.6.1 Migration assay 23 3.6.2 Invasion assay 24 3.6.3 Wound healing assay 24 3.7 Western blotting 25 3.8 Cell viability test 26 3.9 Xenograft study and animal model of irradiation 26 3.9.1 Xenograft study for tumor growth 26 3.9.2 Animal model of irradiation 27 3.10 Clonogenic cell survival assay 27 3.11 Cytometric apoptosis assay 28 3.12 Statistical analysis 28 Chapter 4 Results 30 4.1 The role of tumor-derived IL-6 in OSCC 30 4.1.1 IL-6 expression is an independent prognostic factor for poor survival in OSCC 30 4.1.2 IL-6 promotes OSCC cell growth 31 4.1.3 IL-6 protects cells from radiation-induced apoptosis 33 4.1.4 IL-6 increases radioresistance of OSCC cells through ERK1/2 pathway 34 4.1.5 IL-6/STAT3 axis promotes OSCC cell growth but not radiation response. 36 4.2 The role of CAF-secreted CXCL1 in OSCC 39 4.2.1 CXCL1 is expressed in OSCC tissues and is associated with patient survival 39 4.2.2 Expression of CXCL1 mRNA is upregulated in OSCC tissue and positively correlates with IL-1β expression 40 4.2.3 Tumor-derived IL-1β enhances CXCL1 production in CAFs 41 4.2.4 Tumor-enhanced CXCL1 secretion from CAFs reciprocally stimulates tumor cell invasion 42 4.2.5 Targeting CXCL1 suppresses CAF-augmented cancer cell migration 43 4.2.6 CXCL1-induced MMP-1 gene expression in SAS and CAFs 44 4.3 Summary 45 Chapter 5 Discussion 46 5.1 The results provide new insight about the role of IL-6 in OSCC 46 5.2 This study elucidates the critical CXCL1 signaling in tumor-stromal interaction of OSCC 48 5.3 The connection of the stories 51 Chapter 6 References 53 Chapter 7 Tables 63 Chapter 8 Figures 67 Chapter 9 Future Works 90 9.1 To confirm the role of ERK1/2 in regulation of radioresistance 90 9.2 To investigate the autocrine effect of tumor-derived IL-1β on tumor cells 90 9.3 To test if CXCL1 alters radiation response of OSCC cells 91 9.4 From a single cell to a living body 91 Chapter 10 Appendix 92 10.1 Journal papers related with this thesis 92 10.2 Conferences 92 10.3 Journal papers in preparation 93 | |
dc.language.iso | en | |
dc.title | 細胞激素Interleukin-6與趨化激素CXCL1在口腔鱗狀上皮細胞癌惡化及放射線抗性之角色 | zh_TW |
dc.title | Interleukin-6 and CXCL1 in oral squamous cell carcinoma progression and radioresistance | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 蔡丰喬,成佳憲,郭生興,陳敏慧 | |
dc.subject.keyword | 口腔鱗狀上皮細胞癌,放射線抗性,腫瘤相關纖維母細胞,介白質-1β,介白質-6,趨化激素 CXCL1,基質金屬蛋白-1,腫瘤侵犯,存活率, | zh_TW |
dc.subject.keyword | oral squamous cell carcinoma,radioresistance,cancer-associated fibroblasts,IL-1β,IL-6,CXCL1,matrix metalloproteinase 1,neoplasm invasiveness,survival rate, | en |
dc.relation.page | 93 | |
dc.identifier.doi | 10.6342/NTU201900273 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-01-30 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床牙醫學研究所 | zh_TW |
顯示於系所單位: | 臨床牙醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-F98422011-1.pdf 目前未授權公開取用 | 31.07 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。